This study was designed to evaluate the efficacy of subretinal injection of recombinant adeno-associated virus vector expressing heme oxygenase-1 (rAAV-HO-1) in attenuating photoreceptor apoptosis induced by experimental retinal detachment (RD) in Sprague-Dawley rats. Our results disclosed that subretinal rAAV-HO-1 delivery achieved localized high HO-1 gene expression in retinal outer nuclear layer (ONL) compared with rAAV-lacZ-injected eyes and eyes with RD left untreated both at 2 (p = 0.003) and 28 (p = 0.007) days of RD. The ONL thickness (p = 0.018) and mean photoreceptor nuclei count (p = 0.009) in eyes receiving rAAV-HO-1 injection was significantly higher than in rAAV-lacZ-injected or eyes with RD left untreated at 28 days of RD. There were fewer apoptotic photoreceptor nuclei at 2 (p = 0.008) and 5 (p = 0.018) days of RD and less activated caspase-3 expression (p = 0.008) at 2 days of RD in rAAV-HO-1 treated eyes than in control eyes. These data supported that gene transfer approach might attenuate photoreceptor apoptosis caused by RD with a resultant better ONL preservation.
Introduction
Retinal detachment (RD), the separation of the neurosensory retina from the retinal pigment epithelium (RPE), is a common cause of human visual impairment Hassan et al., 2002; Lewis, Charteris, Sethi, & Fisher, 2002 ; The Eye Disease Case-Control Study Group., 1993 . Due to the recent advancements, the surgical outcome for RD is largely improved, and is associated with fewer complications (Brazitikos, 2000) . However, some patients experience visual impairment despite successful reattachment surgery.
The retinal cells that are most susceptible to detachment are photoreceptors, Müller cells and RPE cells (Fisher, Lewis, Linberg, & Verardo, 2005) . Evidences show that photoreceptors continue to undergo cell death after detachment (Cook, Lewis, Fisher, & Adler, 1995; Fisher & Anderson, 2001; Hisatomi et al., 2002) , and there is a steady decline in the thickness of the retinal outer nuclear layer (ONL) after RD (Erickson, Fisher, Anderson, Stern, & Borgula, 1983; Kubay, Charteris, Newland, & Raymond, 2005; Tanelian, Barry, Johnston, Le, & Smith, 1997 . Photoreceptor cell death after RD has been shown to be associated with apoptosis (Chang, Lai, Edward, & Tsao, 1995; Cook et al., 1995) and is implicated with the poor visual prognosis after RD (Fisher et al., 2005) . Several mediators such as fibroblast growth factor Li, Chang, & Milam, 1997 , ciliary-associated neurotrophic factor Richardson, 1994 , brain-derived neurotrophic factor (Lewis, Linberg, Geller, Guerin, & Fisher, 1999) , and insulin-like growth factor (Burren, Berka, Edmondson, Werther, & Batch, 1996) have been used to reduce the damage to photoreceptors induced by RD in animal studies. Previously, we have reported the use of recombinant adeno-associated virus (rAAV) as a vector expressing glial cell-line-derived neurotrophic factor to protect photoreceptors from apoptosis in experimental RD (Wu et al, 2002) .
The heme oxygenase (HO) is a regulator of oxidative stress (Morita, Perrella, Lee, & Kourembanas, 1995; Otterbein & Choi, 2000; Stocker, Yamamoto, McDonagh, Glazer, & Ames, 1987) . HO catalyzes the oxidative degradation of heme to biliverdin, carbon monoxide (CO), and iron (Guo et al., 2004; Togane et al., 2000) . The heme oxygenase-1 (HO-1) is the 0042-6989/$ -see front matter Ó 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.visres.2008.07.017 inducible isoenzyme of HO (Abraham, Lin, Dunn, & Schwartzman, 1987) and heme oxygenase-2 (HO-2) is the basal constituent isoenzyme of HO (Maines, Trakshel, & Kutty, 1986) . Inhibition of apoptosis has been proposed as a new mechanism for HO-1-mediated cytoprotection (Guo et al., 2004) . The anti-apoptotic role of HO-1 in ischemic heart disease (Guo et al., 2004; Togane et al., 2000) , graft rejection (Otterbein et al., 2003) , ischemia-reperfusion injury (Kukoba, Moibenko, & Kotsioruba, 2003) , and renovascular hypertension (Botros et al., 2007) was reported. Increased heme turnover (Gonzalez-Michaca, Farrugia, Croatt, Alam, & Nath, 2004) and CO production (Reiter & Demple, 2005; Zhang et al., 2003) was demonstrated to be related with HO-1 mediated antiapoptosis. Studies also showed that HO-1 could upregulate the anti-apoptotic p38 MAPK (Zhang et al., 2003) and Bcl2 expression (Reiter & Demple, 2005) and inactivate the pro-apoptotic caspase-3 expression (Tang et al., 2004; Zacks et al., 2003) . In retina, Ulyanova and coworkers reported that HO-1 overexpression could be induced in vitro in Müller cells by conditions of oxidative stress (Ulyanova et al., 2001) . Ocular overexpression of HO-1 was shown to lower intraocular pressure (Privitera, Potenza, Bucolo, Leggio, & Drago, 2007) , reduce reperfusion-induced injury (Szabo et al., 2004) , and protect RPE cells from oxidative stress-induced death (Hanneken, Lin, Johnson, & Maher, 2006) .
Previously, to investigate the therapeutic function of HO-1, its accumulation in stressed tissue was achieved by various pharmaceutical agents and viral vectors (Abraham, 2003; Abraham et al., 1995; Melo et al., 2002; Quan et al., 2004) . Delivery of HO-1 gene had been shown to protect the myocardium from ischemia (Melo et al., 2002) , modulate angiotensin II-induced increase in blood pressure (Yang, Bula, Arroyo, & Chen, 2004) , and protect cultured islets against rTNF-alpha and CHX-mediated cytotoxicity (Li et al., 2006) . Among the various gene delivery vectors, rAAV vectors are highly efficient at gene transfer in vivo (Pan et al., 1999 (Pan et al., , 2000 and can facilitate long-term transduction in animal models of retinal disease such as laser-induced choroidal neovascularization (Lai et al., 2001) , diabetic vascular leakage (Shyong et al., 2007) , and retinal ischemic injury . In this study, to induce the retinal overexpression of HO-1 in the rats' retina, we used rAAV as a vector to deliver HO-1. The effect of retinal HO-1 overexpression on ONL preservation, photoreceptor apoptosis, and activated caspase-3 expression was studied.
Materials and methods

Generation of rAAV-HO-1
The cDNA coding for mouse HO-1 was amplified by polymerase chain reaction (PCR) using a mouse cDNA library as template and the two oligonucleotides 5 0 -GGATCCACCATGGAGCGTCCACAGCCC GAC-3 0 /5 0 -GCGGCCGCTTACATGGCATAAATTCCCA-3 0 as primers. rAAV encoding HO-1 cDNA or lacZ were constructed by using a threeplasmid cotransfection system as described previously (Pan et al., 1999 (Pan et al., , 2000 Wu et al., 2002) . Titers of rAAV-HO-1 and rAAV-lacZ were determined by dot blot hybridization using HO-1 cDNA and lacZ as probes (Sun, Li, & Xiao, 2000; Xiao, Li, & Samulski, 1998) .
Animals
Male Sprague-Dawley rats (SD rats) weighing approximately 200 g on arrival, were used in this study. Four groups of agematched SD rats were studied: normal control SD rats, SD rats with experimental RD left untreated, SD rats receiving subretinal rAAV-HO-1 injection, and SD rats receiving subretinal rAAV-lacZ injection. There were 45 animals in each group. All the animals were cared for in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All experimental procedures used aseptic sterile techniques and were approved by the Animal Care and Use Committee of the Mackay Memorial Hospital.
Subretinal rAAV injection
SD Rats were anesthetized with intramuscular injection of 0.8 mL/kg of an equal-volume mixture of 50 mg/mL ketamine (Ketalar; Parke-Davis, Morris Plains, NJ) and 2% xylazine (Rompun; Bayer AG, Leverkusen, Germany). The right eyes were prepared for subretinal rAAV injection as previously reported (Lai et al., 2001; Sun et al., 2007; Wu et al., 2002) . After pupils were dilated and the eyeballs were protruded with a rubber sleeve, a sclerotomy 1 mm posterior to temporal limbus was made with the tip of a 30-gauge needle. Retinotomy was then made in the temporal peripheral retina with the tip of the 30-gauge needle. A Hamilton syringe equipped with a 33-gauge needle was then introduced through the sclerotomy and retinotomy into the subretinal space and 3 lL of viral suspensions (1.1 Â 10 10 viral particles) was injected. The needle was left in the subretinal space for 1 min after injection to reduce the degree of reflux. Successful injection was confirmed by identifying RD in the temporal retina (Lai et al., 2001; Wu et al., 2002; Zacks et al., 2003) .
Experimental retinal detachment
Three weeks after subretinal rAAV injection, experimental RD was performed in the right eyes of SD rats by subretinal injection of sodium hyaluronate (Healon-GV, Pharmacia and Upjohn) (Hisatomi et al., 2002; Wu et al., 2002; Zacks, Zheng, Han, Bakhru, & Miller, 2004; Zacks et al., 2003) . In brief, after anesthetized and prepared as previously described in subretinal rAAV injection, the sclera was punctured 1 mm posterior to temporal limbus with a 30-gauge needle, and then made a retinotomy in the temporal peripheral retina. A Hamilton syringe equipped with a 33-gauge needle was slowly advanced into the subretinal space. The sodium hyaluronate was slowly injected into subretinal space, causing detachment of the temporal half retina. Eyes with massive subretinal hemorrhage, lens trauma or other complication were excluded. RD was remained essentially stable during the time of study (28 days) which was confirmed in every animal by surgical microscope.
HO-1 activity assay
HO-1 activity assay was performed using a technique (Carraway et al., 2002; Li & Dai, 2004; Tenhunen, Marver, & Schmid, 1968) in which bilirubin concentration, the end product of heme degradation, was determined spectrophotometrically. Briefly, retinas were homogenized in 0.5 mL phosphate buffer (0.1 mmol/L, pH 7.4) and incubated on ice with medium consisting of MgCl 2 (2 mmol/L, Invitrogen, CA, USA), Hemin (50 lmol/L, Fluka, Milano, Italy), NADPH (0.8 mmol/L, Sigma-Aldrich, St. Louis, MO, USA), glucose 6-phosphate (2 mmol/L, Sigma-Aldrich, St. Louis, MO, USA), and glucose-6-phosphate dehydrogenase (0.0016 U/ll, Sigma-Aldrich, St. Louis, MO, USA), liver cytosol (5 mg/mL) for 60 min at 37°C(Abdel Aziz et al., 2007; Carraway et al., 2002; Li & Dai, 2004) . Bilirubin was then extracted with chloroform and measured on a spectrophotometer (Spectra MAX190, Molecular Devices, Sunnyvale, CA, USA) based on optical density (OD) at 464 nm minus 530 nm using an extinction coefficient of 40 mM À1 cm À1 (Carraway et al., 2002; Li & Dai, 2004; Tenhunen et al., 1968) . The values are expressed as nanomoles of bilirubin formed per minute for per milligram protein. An NADPH-free reaction mixture was provided as blank control. (Li & Dai, 2004 ).
Western blot analyses
Retinal expression of HO-1 and activated caspase-3 were detected by Western blot analysis. SD rats were sacrificed in a CO 2 saturated chamber and the eyes were enucleated at 2, 5, 10, and 28 days after creating experimental RD. The retinal tissues were harvested and prepared for soluble fractions by homogenizing the retina in Eppendorf tubes containing RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1 mM EGTA, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml pepstatin (Shyong et al., 2007; Sun et al., 2007; Zacks et al., 2003) . Protein (50 lg) from each animal was extracted for electrophoresis on 10% SDS-polyacrylamide gels, and transferred onto a membrane. The membrane was incubated with antibody specific to HO-1, HO-2, and activated caspase-3 (Abcam, Cambridge, USA). The results were then semiquantified by densitometry analysis (Fujifilm LAS3000, Tokyo, Japan) and normalized using actin levels.
Immunofluorescence assay
SD rats were sacrificed at 2 and 28 days after creating experimental RD, as described previously in Western blot analyses. For orientation, the temporal sclera was sutured with stitches before enucleation. The enucleated eyeballs were fixed in 2% paraformaldehyde for overnight storage and then embedded in paraffin. Retinal tissue sections (5-lm thick) temporal to midline sagittal cut were collected every 60 lm and transferred to positively charged slides. They were dewaxed in xylene, progressively hydrated and then washed three times with phosphate buffer saline and a 1:100 dilution of antibody specific to HO-1 (Abcam, Cambridge, USA) (Cukiernik et al, 2004; Shyong et al., 2007; Sun et al., 2007) . A FITC-conjugated anti-mouse IgG was used as the secondary antibody. The results were then viewed with a fluorescence microscopy (Zeiss Axioplan HBO100, Oberkochen, Germany). The retinas that were found to have reattached on the day of death were excluded from further analysis. To quantify the fluorescence intensity, images randomly from six retinal areas (200 lm 2 ) in each section were photographed with a 20x objective and a similar exposure time of 2.5 s (Andrieu-Soler et al., 2006; Antonetti et al., 1998; Shyong et al., 2007) . The fluorescence intensity of the ONL and the inner nuclear layer (INL) was quantified by using Adobe Photoshop Histogram algorithm (Adobe Systems, San Jose, CA, USA) (Andrieu-Soler et al., 2006; Kirkeby & Thomsen, 2005) . Backgrounds were defined as the fluorescence intensity in non-retinal fields and then subtracted from the values obtained for ONL (Andrieu-Soler et al., 2006; Kinney et al., 2006; Kirkeby & Thomsen, 2005) . Values for fluorescence intensity were then calculated and expressed as means ± SD.
Morphology studies
The SD rats were sacrificed and enucleated for morphology study at 28 days of RD. The temporal sclera was sutured with stitches for orientation. After enucleation, the cornea and lens were removed. The remaining eyecups were placed in fixative containing 1.5% glutaraldehyde and 2% paraformaldehyde at 4°C for overnight storage (Zacks et al., 2003) and then embedded in paraffin. Vertical sections (5-lm thick) temporal to midline were cut through the optic nerve head and collected every 60 lm. These sections were dewaxed in xylene, progressively hydrated and stained with haematoxylin-eosin for histological evaluation (Wu et al., 2002; Zacks et al., 2003) . The retinas that were found to have reattached on the day of death were excluded from further analysis. Measurements of ONL thickness and haematoxylin-eosin positive photoreceptor nuclei of detached retina were taken every 60 lm in each section and combined to obtain an average.
In situ TUNEL labeling
Experimental eyes were obtained 2, 5, 10 days after initiating RD and processed for TUNEL assay. The TUNEL assay was performed with a DNA fragmentation detection kit (Calbiochem, Darmstadt, Germany) on 5-lm thick paraffin-embedded eye sections, as described previously in immunofluorescence assay (Wu et al., 2002) . The TUNEL assay fluorescence signals were viewed with a Zeiss Axioplan HBO 100 fluorescence microscope. The total numbers of TUNEL-positive nuclei every 450 lm of detached retina in each section were counted and combined to obtain an average (Hisatomi et al., 2002; Wu et al., 2002; Zacks et al., 2003) .
Statistical analyses
The results were expressed as means ± SD. We used the Kruskal-Wallis test to compare the differences in ONL thickness, photoreceptor nuclei count, ONL fluorescence intensities, retinal expression of activated caspase-3, and the total numbers of TUN-EL-positive nuclei between eyes receiving rAAV-HO-1 and rAAVlacZ injection and eyes with RD left untreated. All P values are 2-tailed and differences are considered to be statistically significant for p < 0.05.
Results
Overexpression of HO-1 in the retina after subretinal injection of rAAV-HO-1
Fig . 1A shows the retinal overexpression of HO-1 induced by rAAV-HO-1 injection. There was no retinal HO-1 was noted in normal control eye. Minimal HO-1 expression was detected in eyes with RD left untreated and eyes with RD receiving rAAV-lacZ injection at 2 and 5 days of RD. After densitometric quantification, HO-1 expression was significantly increased in rAAV-HO-1 treated eyes at 2 (RD left untreated: 4.12 ± 0.23 pixels, rAAV-HO-1: 17.2 ± 2.25 pixels, rAAV-lacZ: 3.98 ± 0.3 pixels, Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.018), 5 (RD left untreated: 2.90 ± 0.26 pixels, rAAV-HO-1: 16.1 ± 3.34 pixels, rAAV-lacZ: 3.55 ± 0.79 pixels Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.018), 10 (RD left untreated: 2.92 ± 0. 55 pixels, rAAV-HO-1: 15.5 ± 2.0 pixels, rAAV-lacZ: 2.71 ± 0.35 pixels Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.018), and 28 (RD left untreated: 2.67 ± 0.34 pixels, rAAV-HO-1: 14.2 ± 1.98 pixels, rAAV-lacZ: 2.56 ± 0.23 pixels KruskalWallis test, n = 3 from three animals in each group, p = 0.018) days of RD (Fig. 1B) . Retinal expression of HO-2 in normal control eye, eyes with RD left untreated, and eyes with RD receiving rAAV injection was not significantly changed (Fig. 1A) .
The HO-1 activity was measured by the formation of bilirubin in retina (Carraway et al., 2002; Li & Dai, 2004; Tenhunen et al., 1968, Fig. 1C) . It was 1.8 ± 0.21 nmol bilirubin/mg/min in normal control eye. The HO-1 activity was significantly increased in rAAV-HO-1 injected eyes at 2 (RD left untreated: 1.77 ± 0.23 nmol bilirubin/ mg/min, rAAV-HO-1: 16.2 ± 1.01 nmol bilirubin/mg/min, rAAVlacZ: 2.01 ± 0.3 nmol bilirubin/mg/min Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.011), 5 (RD left untreated: 2.12 ± 0.09 nmol bilirubin/mg/min, rAAV-HO-1: 14.0 ± 0.99 nmol bilirubin/mg/min, rAAV-lacZ: 1.98 ± 0.23 nmol bilirubin/mg/min Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.011), 10 (RD left untreated: 2.13 ± 0.11 nmol bilirubin/mg/ min, rAAV-HO-1: 15.5 ± 1.79 nmol bilirubin/mg/min, rAAV-lacZ:
2.03 ± 0.35 nmol bilirubin/mg/min Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.011) and 28 (RD left untreated: 1.77 ± 0.25 nmol bilirubin/mg/min, rAAV-HO-1: 13.5 ± 1.22 nmol bilirubin/mg/min, rAAV-lacZ: 1.98 ± 0.23 nmol bilirubin/mg/min Kruskal-Wallis test, n = 3 from three animals in each group, p = 0.011) days of RD (Fig. 1C) .
To further confirm the induction of HO-1 in the retina after gene transfer, an immunofluorescence assay was performed with an anti-HO-1 antibody. HO-1 immunofluorescence was demonstrated in the retinal ONL of rAAV-HO-1 treated eyes (Fig. 2C ) at 2 days of RD. No HO-1 immunofluorescence was observed in normal control eyes ( Fig. 2A) , eyes with RD left untreated ( Fig. 2B and E) , and rAAV-lacZ treated eyes ( Fig. 2D and G) . HO-1 immunofluorescence was still present in the ONL of rAAV-HO-1 treated eyes at 28 days of RD (Fig. 2F) . These results confirmed the induction of HO-1 expression in rAAV-HO-1 treated retina.
Quantitative analyses of the relative HO-1 fluorescence values in the ONL were 29.61 ± 1.72 for normal control eyes, 31.25 ± 2.56 for eyes with RD left untreated, 85.04 ± 3.12 for rAAV-HO-1 treated eyes, and 29.90 ± 1.00 for rAAV-lacZ-injected eyes at 2 days of RD (Fig. 3) . There was a significant increase in HO-1 fluorescence in rAAV-HO-1 treated eyes compared with rAAV-lacZ treated and eyes with RD left untreated (Kruskal-Wallis test, n = 5 from 5 animals in each group, p = 0.003). At 28 days of RD, relative HO-1 fluorescence values in the ONL were 29.89 ± 1.66 for normal control eyes, 29.9 ± 1.0 for eyes with RD left untreated, 78.06 ± 3.34 for rAAV-HO-1 treated eyes, and 32.86 ± 2.9 for rAAV-lacZ treated eyes (Fig. 3) . As shown previously, HO-1 fluorescence in the ONL was higher in rAAV-HO-1-treated eyes than in rAAV-lacZ-injected eyes or eyes with RD left untreated (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.007).
Morphology and quantitative analysis of the ONL
Twenty-eight days after creating RD, the SD rats were sacrificed and enucleated for morphology study. Representative images were shown in Fig. 4A . Degeneration of the retinal photoreceptor outer segment (OS) and inner segment (IS) was noted in eyes treated with rAAV-lacZ or eyes with RD left untreated compared with normal control eyes. The ONL was significantly shortened in eyes treated with rAAV-lacZ, or eyes with RD left untreated than in rAAV-HO-1 treated eyes and normal control eyes. The quantitative analysis of ONL thickness in the eyes receiving different treatments at 28 days of RD was shown in Fig. 4B . The mean ONL thickness was 42.15 ± 3.18 lm in normal control eyes and 33.11 ± 3.76 lm in rAAV-HO-1 treated eyes. The mean ONL thickness was 26.14 ± 1.86 lm in rAAV-lacZ treated eyes, and 25.56 ± 2.20 lm in eyes with RD left untreated. The ONL thickness (Kruskal-Wallis test, n = 6 from 6 animals in each group, p = 0.018) was significantly preserved in rAAV-HO-1 treated eyes compared with rAAV-lacZ treated eyes at 28 days of RD. The mean photoreceptor nuclei count was 11.5 ± 0.46 rows in normal control eyes and 8.92 ± 0.77 rows in rAAV-HO-1 treated eyes at 28 days of RD. It was 5.90 ± 0.46 rows in rAAV-lacZ treated eyes, and 6.01 ± 0.41 rows in eyes with RD left untreated (Fig. 4C) . The mean photoreceptor nuclei count was significantly higher in rAAV-HO-1 treated eyes compared with rAAV-lacZ treated eyes and eyes with RD left untreated at 28 days of RD (Kruskal-Wallis test, n = 6 from 6 animals in each group, p = 0.009).
Effects of HO-1 overexpression on photoreceptor apoptosis
The eyes were enucleated for TUNEL assay at 2, 5, and 10 days after creation of RD. Representative images of eyes receiving different treatments are shown in Fig. 5A . No TUNEL-positive nuclei were observed in normal control eyes. Representative images at 2 days of RD disclosed that there were fewer TUNEL-positive nuclei in the ONL of detached retina in rAAV-HO-1 treated eyes compared with eyes treated with rAAV-lacZ and eyes with RD left untreated. After counting TUNEL-positive nuclei in the retina, the mean apoptotic cells per 450 lm of retina was 3.38 ± 0.59 in rAAV-HO-1 treated eyes, 10.90 ± 1.99 in rAAV-lacZ treated eyes, and 11.12 ± 1.23 in eyes with RD left untreated at 2 days of RD. The apoptotic cells diminished gradually at 5 and 10 days of RD. The mean apoptotic cells per 450 lm of retina at 5 days of RD was 4.02 ± 0.45 in rAAV-HO-1 treated eyes, 8.11 ± 1.13 in rAAV-lacZ treated eyes, and 7.55 ± 0.99 in eyes with RD left untreated. At 10 days of RD, the mean apoptotic cells per 450 lm of retina was 3.01 ± 0.58 in rAAV-HO-1 treated eyes, 3.79 ± 0.4 in rAAV-lacZ treated eyes, and 4.06 ± 0.62 in eyes with RD left untreated. Quantitative analysis showed that there was significantly fewer TUNEL-positive nuclei in rAAV-HO-1 treated eyes than in rAAV-lacZ treated eyes and eyes with RD left untreated at 2 (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.008) and 5 days (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.018)of RD (Fig. 5B) . There was no statistical difference at 10 days of RD between eyes treated with either rAAV-HO-1, rAAV-lacZ or eyes with RD left untreated (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.45).
Effects of HO-1 overexpression on activated caspase-3 expression
Eyes receiving different treatments were enucleated at 2, 5, and 10 days of RD for Western blot analysis using antibodies specific for activated caspase-3. The retinal expression of activated caspase-3 was higher in eyes treated with rAAV-lacZ and eyes with RD left untreated compared with normal control eyes and rAAV-HO-1 treated eyes at 2 days of RD (Fig. 6A) . After that, it gradually diminished. Quantified activated retinal capase-3 was 4.00 ± 0.55 pixels in normal control eye, At 2 days of RD, it was 7.75 ± 0.89 pixels in rAAV-HO-1 treated eyes, 14.29 ± 1.15 pixels in rAAV-lacZ treated eyes, and 15.35 ± 1.21 pixels in eyes with RD left untreated (Fig. 6B) . The activated caspase-3 at 5 days of RD was 4.92 ± 1.12 pixels in rAAV-HO-1 treated eyes, 6.34 ± 0.99 in rAAV-lacZ treated eyes, and 5.12 ± 0.78 pixels in eyes with RD left untreated. At 10 days of RD, the retinal activated caspasse-3 was 4.76 ± 0.46 pixels in rAAV-HO-1 treated eyes, 4.93 ± 0.78 pixels in rAAV-lacZ treated eyes, and 5.33 ± 1.09 pixels in eyes with RD left untreated. Quantitative analysis showed that the activated caspase-3 induced by experimental RD was significantly reduced in rAAV-HO-1 treated eyes compared with rAAV-lacZ treated eyes (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.008) at 2 days of RD. There was no statistical difference at 5 (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.23) and 10 (Kruskal-Wallis test, n = 5 from five animals in each group, p = 0.45) days of RD between eyes treated with either rAAV-HO-1, rAAV-lacZ or eyes with RD left untreated.
Discussion
RD is a common cause of visual impairment in humans (Lewis et al., 2002) . Unfortunately, RD patients may suffer from visual impairment even after successful reattachment surgery (Brazitikos, 2000; Hisatomi et al., 2002) . Photoreceptor apoptosis has been implicated in poor visual prognosis after RD (Erickson et al., 1983; Fisher & Anderson, 2001 ). This study was designed to evaluate the protective efficacy of retinal HO-1 overexpression in attenuating the photoreceptor apoptosis caused by experimental RD. To induce HO-1 overexpression, subretinal HO-1 gene delivery via a rAAV vector was used. Our results showed that there were fewer apoptotic photoreceptors (Figs. 5 and 6) in rAAV-HO-1 treated eyes compared with rAAV-lacZ-treated eyes and RD left untreated eyes. At 28 days of RD, the ONL was much more preserved in eyes treated with rAAV-HO-1 than in eyes treated with rAAV-lacZ and RD left untreated eyes (Fig. 4) . These results suggest that rAAV-mediated HO-1 gene delivery in the retina may attenuate the photoreceptor death induced by experimental RD.
HO-1 is an enzyme that can catalyze the oxidative degradation of heme to biliverdin, CO, and iron (Otterbein et al., 2000b; Guo et al., 2004; Morita et al., 1995; Stocker et al., 1987; Togane et al., 2000) . The anti-apoptotic effect of HO-1 overexpression was disclosed in ischemic heart disease (Guo et al., 2004; Togane et al., 2000) , graft rejection (Otterbein et al., 2003) , and renovascular hypertension (Botros et al., 2007) . In retina, it was reported that HO-1 could be induced after hypoxia (Ulyanova et al., 2001) , ischemia-reperfusion injury (Szabo et al., 2004) , and intense light exposure (Sun et al., 2007) . Evidences showed that over-expressed HO-1 could increase heme turnover (Gonzalez-Michaca et al., 2004) , increase CO production (Reiter & Demple, 2005; Zhang et al., 2003) , and inactivate the pro-apoptotic caspase-3 expression (Guo et al., 2004; Tang et al., 2004; Togane et al., 2000; Zacks et al., 2003) . Recently, there were growing evidences disclosed that CO could also upregulate antiapoptotic p38 MAPK (Zhang et al., 2003) and Bcl2 expression (Reiter & Demple, 2005) . CO releasing molecules have also been developed to facilitate CO delivery and lacked the ability to induce HO-1 (Motterlini et al., 2002) . More experiments are necessary to evaluate if CO could have a similar effect as rAAV-HO-1 in attenuating RD induced photoreceptor apoptosis.
The photoreceptor apoptosis induced by experimental RD was reported to be activated by the FAS/FAS ligand system (Zacks et al., 2003; Zacks et al., 2004) or through an intrinsic pathway modified by intracellular proteins (Hisatomi et al., 2002) . TUNELpositive apoptotic photoreceptors appeared to reach a maximum on day 3 of RD and gradually diminished (Hisatomi et al., 2002) . Time dependent caspase-3 activation played an important role in the transduction pathway of the apoptotic cascade (Cook et al., 1995; Zacks et al., 2003) . Modulation of the apoptotic cascade has been shown to alter the rate and amount of photoreceptor apoptosis in animal models of RD Zacks et al., 2003; Zacks et al., 2004) . In the present study, we showed that less activated caspase-3 expression at 2 days of RD (Fig. 6 ) accompanied with fewer TUNEL-positive nuclei in ONL at 2 and 5 days of RD (Fig. 5) was noted in rAAV-HO-1 treated eyes compared with rAAV-lacZ treated eyes or RD left untreated eyes. Combined these findings, it supported an important role of HO-1 in attenuating photoreceptor apoptosis induced by experimental RD through modulation of caspase-3 activation. This effect might contribute to better preservation of visual function in RD patients.
By use of a viral vector delivering HO-1 gene, overexpression of HO-1 was shown to protect the myocardium from ischemia (Melo et al., 2002) , modulate angiotensin II-induced increase in oxidative injury (Quan et al., 2004) , and protect cultured islets against rTNFalpha and CHX-mediated cytotoxicity (Li et al., 2006) . The rAAV vectors were demonstrated to be capable of mediating efficient and prolonged transgene expression (Bainbridge, Tan, & Ali, 2006; Rolling, 2004) . Our previous works demonstrated that rAAV vectors were highly efficient gene-delivery systems which could facilitate long-term transduction in animal models of retinal diseases (Lai et al., 2001; Shyong et al., 2007; Wu et al., 2002 Wu et al., , 2004 . In this study, we reported that subretinal delivery of HO-1 gene via a rAAV vector induced HO-1 overexpression in the retinal ONL (Fig. 2) . However, increased HO-1 expression is not an indication of increased HO-1 activity (Sardana & Kappas, 1987) . We measured HO-1 activity by the formation of bilirubin in retina (Carraway et al., 2002; Li & Dai, 2004; Tenhunen et al., 1968) and disclosed increased HO-1 expression by rAAV-HO-1 was accompanied with increased HO-1 activity (Fig. 1C) . This transgenic rAAV-HO-1 expression led to attenuate RD induced photoreceptor apoptosis associated with better ONL preservation without repeated subretinal injection.
Evidences disclosed that HO-1 was induced mainly in Müller cells, but not photoreceptors, after exposure to stressful stimuli (Szabo et al., 2004; Ulyanova et al., 2001 ) and intense light (Sun et al., 2007) . Due to its anti-apoptotic ability, overexpression of HO-1 in photoreceptor might protect them from RD-induced apoptosis. In the retina, following subretinal delivery, rAAV vectors could transduce RPE and photoreceptor (Ali et al.,1996; Ali et al., 1998; Bennett et al., 1999) . In present study, we demonstrated that localized high HO-1 gene expression was noted in the ONL after subretinal injection of rAAV-HO-1 (Fig. 4) . Thus, it seems that specific and high expression of HO-1 in the ONL after subretinal injection is essential to attenuate photoreceptor apoptosis induced by RD (Kinney et al., 2006) . This report demonstrates that overexpression of HO-1 can reduce the photoreceptor apoptosis induced by experimental RD. Our results showed that subretinal rAAV-HO-1 injection could lead retinal HO-1 overexpression localized in ONL. Transduction of HO-1 gene by rAAV in the retina provided a better protection from RD-induced apoptosis. This novel strategy could offer the benefit of a long-lasting protective effect without the need for repeated injection. These advantages could serve as the basis for an adjunctive treatment for patients suffering from RD to reduce the risk of permanent visual loss even after successful reattachment surgery.
